Nesibe KAHRAMAN ÇETİN, İbrahim METEOĞLU, Emin BOZKURT, İbrahim Halil ERDOĞDU

Evaluation of the Mutation Profile via Next-Generation Sequencing in a Turkish Population with Non-small Cell Lung Cancer

Background: Lung cancer is the most common cancer type worldwide, with non-small cell lung cancer being the most frequently studied. Identifying of cancer-related genes in non-small cell lung cancer is crucial for developing individualized treatment, particularly as mutation profiles can vary by country and ethnicity. Aims: To identify comprehensive mutation profiles in a cohort of Turkish patients with non-small cell lung cancer using the next-generation sequencing. Study Design: Retrospective cross-sectional study. Methods: In total, 72 cancer-related genes and 4149 variants were recorded in the non-small cell lung cancer panel, and their relationship with clinical and histopathological features was investigated through next-generation sequencing. Results: Among 507 patients, 420 (82.8%) were males and 87 (17.2%) were females. Percentages of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (11%), B-Raf proto-oncogene, serine/ threonine kinase (8%), and neurofibromatosis type 1 (6%) mutations were higher than those reported in the literature. Males had a higher rate of Kirsten rat sarcoma 2 viral oncogene homolog mutations (P = .102), whereas epidermal growth factor receptor mutations were statistically more common in females (P = .001). Multiple variants of strong significance were identified in 6.3% patients diagnosed with adenocarcinoma, most of whom were smokers. Kirsten rat sarcoma 2 viral oncogene homolog and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha mutations were most commonly observed. Conclusion: This study shows that Turkish patients have higher rates of PIK3CA, BRAF and NF1 mutations compared to the literature. Studies to determine the molecular profile specific to Turkish people will guide clinicians in treatment and contribute significantly to determining priorities in diagnosis.

PDF

___

1. Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG, FRCPath. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: International Agency for Research on Cancer (IARC); 2015:11-112.
2. Öz B. Targeted treatments in lung cancer. Toraks Cerrahisi Bul. 2017;10:39-44.
3. Bozkurtlar E, Kaya H. Molecular pathology of lung cancer. Nucl Med Semin. 2018;4(1):26-31. [CrossRef]
4. Gridelli C, Rossi A, Carbone DP, et al. Non-small-cell lung cancer. Nat Rev Dis Primers. 2015;1:15009. [CrossRef]
5. Jiang R, Zhang B, Teng X, et al. Validating a targeted next-generation sequencing assay and profiling somatic variants in Chinese non-small-cell lung cancer patients. Sci Rep. 2020;10(1):2070. [CrossRef]
6. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7-30. [CrossRef]
7. Cheng L, Zhang S, Alexander R, et al. The landscape of EGFR pathways and personalized management of non-small-cell lung cancer. Future Oncol. 2011;7(4):519- 541. [CrossRef]
8. Zhang Y, Shen WX, Zhou LN, et al. The value of next-generation sequencing for treatment in non-small-cell lung cancer patients: the observational, real-world evidence in China. BioMed Res Int. 2020;2020:9387167. [CrossRef]
9. Mayo-de-Las-Casas C, Jordana-Ariza N, Garzón-Ibañez M, et al. Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisions. Ann Oncol. 2017;28(9):2248-2255. [CrossRef]
10. Kerr KM, Bubendorf L, Edelman MJ, et al. Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Ann Oncol. 2014;25(9):1681-1690. [CrossRef]
11. Hagemann IS, Devarakonda S, Lockwood CM, et al. Clinical next-generation sequencing in patients with non-small-cell lung cancer. Cancer. 2015;121(4):631- 639. [CrossRef]
12. Gupta P, Saha K, Vinarkar S, et al. Next generation sequencing in lung cancer: an initial experience from India. Curr Probl Cancer. 2020;44(3):100562. [CrossRef]
13. Chennagiri N, White EJ, Frieden A, et al. Orthogonal NGS for high throughput clinical diagnostics. Sci Rep. 2016;6:24650. [CrossRef]
14. Tan DSW, Mok TSK, Rebbeck TR. Cancer genomics: diversity and disparity across ethnicity and geography. J Clin Oncol. 2016;34(1):91-101. [CrossRef]
15. Ulas A, Tokluoglu S, Kos M, et al. Lung cancer in women, a different disease: survival differences by sex in Turkey. Asian Pac J Cancer Prev. 2015;16(2):815-822. [CrossRef]
16. Ma BB, Hui EP, Mok TS. Population based differences in treatment outcome following anti-cancer drug therapies. Lancet Oncol. 2010;11(1):75-84. [CrossRef]
17. Buyuksimsek M, Togun M, Oguz KI, et al. Results of liquid biopsy studies by next generation sequencing in patients with advanced stage non-small-cell lung cancer: single center experience from Turkey. Balkan J Med Genet. 2019;22(2):17-24. [CrossRef]
18. Erdoğdu Hİ. Next-generation sequencing (NGS): our results of molecular pathology malignant solid tumor panel. Int J Adv Res. 2019;7(1):306-311. [CrossRef]
19. Dogan M, Demirkazik A, Tukun A, et al. The relationship Between common EGFR, BRAF, KRAS mutations and prognosis in advanced stage non-small-cell lung cancer with response to the treatment in Turkey. Int J Hematol Oncol. 2014;24(1):1-10. [CrossRef]
20. Ekinci S, Ilgin-Ruhi H, Dogan M, et al. Molecular spectrum of PIK3CA gene mutations in patients with non-small-cell lung cancer in Turkey. Genet Test Mol Biomarkers. 2015;19(7):353-358. [CrossRef]
21. Güler Tezel GG, Şener E, Aydın Ç, Önder S. Prevalence of epidermal growth factor receptor mutations in patients with non-small cell lung cancer in Turkish population. Balkan Med J. 2017;34(6):567-571. [CrossRef]
22. Li MM, Datto M, Duncavage EJ, et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn. 2017;19(1):4-23. [CrossRef]
23. Iyer S, Prajapati R, Ramesh A, et al. The future of lung cancer therapy: striding Beyond conventional EGFR and ALK treatments. Mol Clin Oncol. 2019;10(4):469- 475. [CrossRef]
24. Oxnard GR, Binder A, Jänne PA. New targetable oncogenes in non-small-cell lung cancer. J Clin Oncol. 2013;31(8):1097-1104. [CrossRef]
25. Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med. 2010;363(4):301-304. [CrossRef]
26. Redig AJ, Capelletti M, Dahlberg SE, et al. Clinical and molecular characteristics of NF1-mutant lung cancer. Clin Cancer Res. 2016;22(13):3148-3156. [CrossRef]
27. Lindeman NI, Cagle PT, Aisner DL, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the college of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch Pathol Lab Med. 2018;142(3):321-346. [CrossRef]
28. Basdemirci M, Zamani A, Zamani AG, Findik S, Yildirim MS. Extended-spectrum of KRAS and NRAS mutations in lung cancer tissue specimens obtained with bronchoscopy. Indian J Cancer. 2021:766-719. [CrossRef]
29. Sholl LM, Aisner DL, Varella-Garcia M, et al. Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: the lung cancer mutation consortium experience. J Thorac Oncol. 2015;10(5):768-777. [CrossRef]